Inhaled corticosteroids plus long-acting β₂-agonists as a combined therapy in asthma

Bibliography

• Global strategy for asthma management and prevention. National Institutes of Health. National Heart, Lung, and Blood Institute (2002) Bethseda, MD, USA.
   Google Scholar
• VIGNOLA AM, CHANEZ P, CAMPBELL AM et al.: Airway inflammation in mild intermittent and in persistent asthma. Am. J. Respir. Grit. Care Med. (1998) 157:403–409.
   PubMed Web of Science ®Google Scholar
• CHETTA A, FOREST A, DEL DONNO M, BERTORELLI G, PESCI A, OLIVIERI D: Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest (1997) 111:852–857.
   PubMed Web of Science ®Google Scholar
• ISRAEL E, BANERJEE TR, FITZMAURICE GM, KOTLOV TV, LAHIVE K, LEBOFF MS: Effects of inhaled glucocorticoids on bone density in premenopausal women. N. EngL J. Med. (2001) 345:941–947.
   PubMed Web of Science ®Google Scholar
• CHAY OM, GOH A, LIM WH, LEONG KH, LOU J: Effects of inhaled corticosteroid on bone turnover in children with bronchial asthma. Respirology (1999) 4:63–67.
   PubMedGoogle Scholar
• MACKENZIE C: Effects of inhaled corticosteroids on growth. J Allergy Clin. ImmunoL (1998) 101:S451–S455.
   Google Scholar
• PRICE JF: Inhaled corticosteroids: clinical relevance of safety measures. Pediatr. PulmonoL (1997) 15(Suppl.):40–45.
   Google Scholar
• ALLEN DB, MULLEN M, MULLEN B: A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J. Allergy ImmunoL (1994) 93:967–976.
   PubMed Web of Science ®Google Scholar
• CUMMING RG, MITCHELL P: Inhaled corticosteroids and cataract: prevalence, prevention and management. Drug Saf (1999) 20:77–84.
   PubMedGoogle Scholar
• CAMPBELL LM, ANDERSON TJ, PARASHCHAK MR, BURKE CM, WATSON SA, TURBITT ML: A comparison of the efficacy of long-acting firagonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group. Respir. Med. (1999) 93:236–244.
   Google Scholar
• LIP WORTH BJ, DEMPSEY 0J, AZIZ I: Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 I32-adrenoceptor polymorphism. Chest (2000) 118:321–328.
   PubMedGoogle Scholar
• NIGHTINGALE JA, ROGERS DF, BARNES PJ: Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest (2002) 121:1401–1406.
   PubMed Web of Science ®Google Scholar
• PALMQVIST M, PERSSON G, LAZER L, ROSENBORG J, LARSSON P, LOTVALL J: Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. (1997) 10:2484–2489.
   PubMed Web of Science ®Google Scholar
• PALMQVIST M, IBSEN T, MELLEN A, LOTVALL J: Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J Respir. Grit. Care Med. (1999) 160:244–249.
   PubMed Web of Science ®Google Scholar
• PALMQVIST M, ARVIDSSON P, BECKMAN 0, PETERSON S, LOTVALL J: Onset of bronchodilation of budesonide/formoterol vs. salmeterol/ fluticasone in single inhalers. Pulm. PharmacoL Ther. (2001) 14:29–34.
   PubMed Web of Science ®Google Scholar
• POLITIEK MJ, BOORSMA M, AALBERS R: Comparison of formoterol, salbutarnol and salmeterol in methacholine-induced severe bronchoconstriction. Eur. Respir. J. (1999) 13:988–992.
   PubMed Web of Science ®Google Scholar
• RUTTEN-VAN MOLKEN MP, VAN DOORSLAER EK, TILL MD: Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics (1998) 14:671–684.
   PubMedGoogle Scholar
• VAN NOORD JA, SMEETS JJ, RAAIJMAKERS JA, BOMMER AM, MAESEN FP: Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur. Respir. (1996) 9:1684–1688.
   PubMed Web of Science ®Google Scholar
• LUNDBACK B, RAWLINSON DW, PALMER JB: Twelve month comparison of salmeterol and salbutarnol as dry powder formulations in asthmatic patients. European Study Group. Thorax (1993) 48:148–153.
   Google Scholar
• KEMP JP, DEGRAFF AC Jr, PEARLMAN DS et al.: A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine. J. Allergy Clin. Immunol. (1999) 104:1189–1197.
   PubMed Web of Science ®Google Scholar
• LOTVALL J, LUNDE H, ULLMAN A, TORNQVIST H, SVEDMYR N: Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on132-receptor function and inflammatory cells. Allergy (1992) 47:477–483.
   Google Scholar
• RAMAGE L, LIPWORTH BJ, INGRAM CG, CREE IA, DHILLON DP: Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. (1994) 88:363–368.
   PubMed Web of Science ®Google Scholar
• SIMONS FE, GERSTNER TV, CHEANG MS: Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics (1997) 99:655–659.
   PubMed Web of Science ®Google Scholar
• STEFFENSEN I, FAURSCHOU P, RISKA H, ROSTRUP J, WEGENER T: Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutarnol, followed by a 12-month trial with formoterol. Allergy (1995) 50:657–663.
   Google Scholar
• GUHAN AR, COOPER S, OBORNE J, LEWIS S, BENNETT J, TATTERSFIELD AE: Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax (2000) 55:650–656.
   PubMed Web of Science ®Google Scholar
• BARTOW RA, BROGDEN RN: Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs (1998) 55:303–322.
   Google Scholar
• MCI VOR RA, PIZZICHINI E, TURNER MO, HUSSACK P, HARGREAVE FE, SEARS MR: Potential masking effects of salmeterol on airway inflammation in asthma. Am. J Respir. Grit. Care Med. (1998) 158:924–930.
   PubMedGoogle Scholar
• SONT JK, WILLEMS LN, BEL EH, VAN KRIEKEN JH, VANDENBROUCKE JP, STERK PJ: Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am. J. Respir. Grit. Care Med. (1999) 159:1043–1051.
   PubMed Web of Science ®Google Scholar
• SHREWSBURY S, PYKE S, BRITTON M: Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. (2000) 320:1368–1373.
   PubMed Web of Science ®Google Scholar
• ••Extensive meta-analysis including most ofthe trials involving BDP and FR
   Google Scholar
• PAUWELS RA, LOFDAHL CG, POSTMA DS et al.: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. (1997) 337:1405–1411.
   Google Scholar
• ••First trial comparing formoterol plus BUDto higher doses of BUD.
   Google Scholar
• MATZ J, EMMETT A, RICKARD K, KALBERG C: Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin. Immunol. (2001) 107:783–789.
   PubMed Web of Science ®Google Scholar
• WALLIN A, SANDSTROM T, SODERBERG M et al.: The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am. J. Respir. Grit. Care Med. (1999) 159:79–86.
   PubMed Web of Science ®Google Scholar
• GARDINER PV, WARD C, BOOTH H, ALLISON A, HENDRICK DJ, WALTERS EH: Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am. J. Respir. Grit. Care Med. (1994) 150:1006–1011.
   PubMed Web of Science ®Google Scholar
• KRAFT M, WENZEL SE, BETTINGER CM, MARTIN RJ: The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest (1997) 111:1249–1254.
   PubMed Web of Science ®Google Scholar
• KIPS JC, O'CONNOR BJ, INMAN MD, SVENSSON K, PAUWELS RA, O'BYRNE PM: A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am. J Respir. Grit. Care Med. (2000) 161:996–1001.
   PubMedGoogle Scholar
• GREENING AP, IND PW, NORTHFIELD M, SHAW G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet (1994) 344:219–224.
   PubMed Web of Science ®Google Scholar
• ••First trial evaluating a LABA added to anICS in relation to a double dose of ICS.
   Google Scholar
• WOOLCOCK A, LUNDBACK B, RINGDAL N, JACQUES LA: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J Respir. Grit. Care Med. (1996) 153:1481–1488.
   PubMed Web of Science ®Google Scholar
• VERBERNE AA, FROST C, DUIVERMAN EJ, GROL MH, KERREBIJN KF: Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am. J Respir. Grit. Care Med. (1998) 158:213–219.
   PubMed Web of Science ®Google Scholar
• ••First trial on the combination of LABAsand ICS in children.
   Google Scholar
• KELSEN SG, CHURCH NL, GILLMAN SA et al.: Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J. Asthma (1999) 36:703–715.
   PubMed Web of Science ®Google Scholar
• MURRAY JJ, CHURCH NL, ANDERSON WH et al.: Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc. (1999) 20:173–180.
   PubMed Web of Science ®Google Scholar
• VERMETTEN FA, BOERMANS AJ, LUITEN WD, MULDER PG, VERMUE NA: Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. J. Asthma (1999) 36:97–106.
   PubMed Web of Science ®Google Scholar
• NIELSEN LP, PEDERSEN B, FAURSCHOU P, MADSEN F, WILCKE JT, DAHL R: Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. Respir. Med. (1999) 93:863–868.
   PubMedGoogle Scholar
• ••Step-down trial introducing the concept ofMAD.
   Google Scholar
• JUNIPER EF, SVENSSON K, O'BYRNE PM et al.: Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. (1999) 14:1038–1043.
   Google Scholar
• ••Trial on the combination of BUD andformoterol centred on the quality of life improvements of the combination therapy.
   Google Scholar
• O'BYRNE PM, BARNES PJ, RODRIGUEZ-ROISIN R et al.: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir. Grit. Care Med. (2001) 164:1392–1397.
   Google Scholar
• ••Evaluates steroid naive patients andpatients already on ICS. Combination of BUD and formoterol.
   Google Scholar
• WEERSINK EJ, DOUMA RR, POSTMA DS, KOETER GH: Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am. J. Respir. Grit. Care Med. (1997) 155:1241–1246.
   PubMedGoogle Scholar
• ••First trial evaluating the combination ofFP and salmeterol.
   Google Scholar
• LAU HY, WONG PL, LAI CK: Effects of firadrenergic agonists on isolated guinea pig lung mast cells. Agents Actions (1994) 42:92–94.
   PubMedGoogle Scholar
• TAYLOR DA, JENSEN MW, AIKMAN SL, HARRIS JG, BARNES PJ, O'CONNOR BJ: Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am. J. Respir. Grit. Care Med. (1997) 156:1731–1737.
   PubMedGoogle Scholar
• ROBERTS JA, BRADDING P, BRITTEN KM et al.: The long-acting 02-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur. Respir. J. (1999) 14:275–282.
   PubMed Web of Science ®Google Scholar
• BARANIUK J, MURRAY JJ, NATHAN RA et al.: Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest (1999) 116:625–632.
   PubMedGoogle Scholar
• CONDEMI JJ, GOLDSTEIN S, KALBERG C, YANCEY S, EMMETT A, RICKARD K: The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann. Allergy Asthma Immunol. (1999) 82:383–389.
   PubMed Web of Science ®Google Scholar
• VAN NOORD JA, SCHREURS AJ, MOL SJ, MULDER PG: Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax (1999) 54:207–212.
   PubMed Web of Science ®Google Scholar
• PEARLMAN DS, STRICKER W, WEINSTEIN S et al.: Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann. Allergy Asthma Immunol. (1999) 82:257–265.
   PubMed Web of Science ®Google Scholar
• JENKINS C, WOOLCOCK AJ, SAARELAINEN P, LUNDBACK B, JAMES MH: Salmeterol/fluticasone propionate combination therapy 50/250 lig twice daily is more effective than budesonide 800 lig twice daily in treating moderate to severe asthma. Respir. Med. (2000) 94:715–723.
   PubMed Web of Science ®Google Scholar
• BAUMGARTEN C, GELDSZUS R, BEHRE U, PESLIS N, TRAUTMANN M: Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 lig) combination product (SAS 40023). Eur. J. Med Res. (2002) 7:1–7.
   PubMedGoogle Scholar
• ••Benefits of a fixed dose of FP andsalmeterol in a single inhaler on steroid naive patients.
   Google Scholar
• FOWLER SJ, CURRIE GP, LIP WORTH BJ: Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J. Allergy Clin. Immunol. (2002) 109:929–935.
   PubMed Web of Science ®Google Scholar
• FAIRFAX A, HALL I, SPELMAN R: A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann. Allergy Asthma Immunol. (2001) 86:575–582.
   PubMed Web of Science ®Google Scholar
• FAURSCHOU P, STEFFENSEN I, JACQUES L: Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. Eur. Respir. J. (1996) 9:1885–1890.
   PubMed Web of Science ®Google Scholar
• ••Trial evaluating salmeterol or salbutamolas add-on therapies for ICS.
   Google Scholar
• AUBIER M, PIETERS WR, SCHLOSSER NJ, STEINMETZ KO: Salmeterol/fluticasone propionate (50/500 pig) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir. Med. (1999) 93:876–884.
   Google Scholar
• ••First trial comparing the combinationtherapy in one single inhaler or two different inhalers.
   Google Scholar
• CHAPMAN KR, RINGDAL N, BACKER V, PALMQVIST M, SAARELAINEN S, BRIGGS M: Salmeterol and fluticasone propionate (50/250 pig) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can. Respir. (1999) 6:45–51.
   PubMedGoogle Scholar
• VAN DEN BERG NJ, OSSIP MS, HEDEROS CA, ANTTILA H, RIBEIRO BL, DAVIES PI: Salmeterol/fluticasone propionate (50/100 pig) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr. Pulmonol. (2000) 30:97–105.
   PubMedGoogle Scholar
• ••Only trial comparing the combination therapy using one or two inhalers in children.
   Google Scholar
• ZETTERSTROM 0, BUHL R, MELLEM H et al.: Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J. (2001) 18:262–268.
   Google Scholar
• ••First trial using the combinationformoterol and BUD in a single inhaler.
   Google Scholar
• KAVURU M, MELAMED J, GROSS G et al.: Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. (2000) 105:1108–1116.
   PubMed Web of Science ®Google Scholar
• SHAPIRO G, LUMRY W, WOLFE J et al.: Combined salmeterol 50 pg and fluticasone propionate 250 pg in the diskus device for the treatment of asthma. Am. J. Respir. Grit. Care Med. (2000) 161:527–534.
   PubMed Web of Science ®Google Scholar
• PEARLMAN DS, WHITE MV, LIEBERMAN AK et al.: Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann. Allergy Asthma Immunol. (2002) 88:227–235.
   PubMed Web of Science ®Google Scholar
• ••Extensive trial comparing the combinationof salmeterol and FP to montelukast.
   Google Scholar
• CALHOUN WJ, NELSON HS, NATHAN RA et al.: Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting 02-agonists alone. Am. J. Respir. Grit. Care Med (2001) 164:759–763.
   PubMed Web of Science ®Google Scholar
• BATEMAN ED, SILINS V, BOGOLUBOV M: Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 pg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir. Med. (2001) 95:136–146.
   PubMed Web of Science ®Google Scholar
• ••Comparison of two different inhalers withthe combination salmeterol and FR
   Google Scholar
• BUSSE W, NELSON H, WOLFE J, KALBERG C, YANCEY SW, RICKARD KA: Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J. Allergy Clin. Immunol. (1999) 103:1075–1080.
   PubMed Web of Science ®Google Scholar
• ••Comparison of salmeterol and zafirlukastas add-on therapy to ICS.
   Google Scholar
• NELSON HS, NATHAN RA, KALBERG C, YANCEY SW, RICKARD KA: Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. Med. Gen. Med. (2001) 3(4):3
   PubMedGoogle Scholar
• YURDAKUL AS, CALISIR HC, TUNCTAN B, OGRETENSOY M: Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir. Med. (2002) 96:322–329.
   PubMedGoogle Scholar
• ••Comparison of zafirlukast, salmeterol andtheophylline as add-on therapies to BUD.
   Google Scholar
• BJERMER L, BISGAARD H, BOUSQUET J et al.: Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). Respir. Med. (2000) 94:612–621.
   PubMed Web of Science ®Google Scholar
• DEMPSEY 0J, WILSON AM, SIMS EJ, MISTRY C, LIP WORTH BJ: Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest (2000) 117:950–953.
   PubMedGoogle Scholar
• WILSON AM, DEMPSEY 0J, SIMS EJ, LIP WORTH BJ: Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest (2001) 119:1021–1026.
   PubMed Web of Science ®Google Scholar
• NELSON HS, BUSSE WW, KERWIN E et al.: Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin. Immunol. (2000) 106:1088–1095.
   PubMed Web of Science ®Google Scholar
• ••First trial comparing salmeterol andmontelukast as add-on therapies to ICS.
   Google Scholar
• FISH JE, ISRAEL E, MURRAY JJ et al.: Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest (2001) 120:423–430.
   PubMed Web of Science ®Google Scholar
• STEMPEL DA, O'DONNELL JC, MEYER JW: Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J. Allergy Clin. Immunol. (2002) 109:433–439.
   PubMedGoogle Scholar
• WHELAN CJ, JOHNSON M, VARDEY CJ: Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br. J Pharmacol. (1993) 110:613–618.
   PubMed Web of Science ®Google Scholar
• ADVENIER C, QIAN Y, KOUNE JD, MOLIMARD M, CANDENAS ML, NALINE E: Formoterol and salbutarnol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig. Br. J Pharmacol. (1992) 105:792–798.
   PubMed Web of Science ®Google Scholar
• BALUK P, MCDONALD DM: The firadrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am. J Physiol. (1994) 266:L461–L468.
   PubMed Web of Science ®Google Scholar
• WILSON SJ, WALLIN A, DELLA-CIOPPA G, SANDSTROM T, HOLGATE ST: Effects of budesonide and formoterol on NF-KB, adhesion molecules, and cytokines in asthma. Am. J Respir. Grit. Care Med. (2001) 164:1047–1052.
   PubMed Web of Science ®Google Scholar
• BACCI E, DI FRANCO A, BARTOLI ML et al.: Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur. Respir. J. (2002) 20:66–72.
   PubMedGoogle Scholar
• WALTERS EH, BJERMER L, FAURSCHOU P, SANDSTROM T: The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients. Respir. Med. (2000) 94(Suppl. F):526–531.
   Google Scholar
• TURNER MO, JOHNSTON PR, PIZZICHINI E, PIZZICHINI MM, HUSSACK PA, HARGREAVE FE: Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can. Respir. J. (1998) 5:261–268.
   PubMedGoogle Scholar
• SEKUT L, CHAMPION BR, PAGE K, MENIUS JA Jr, CONNOLLY KM: Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin. Exp. Immunol. (1995) 99:461–466.
   PubMed Web of Science ®Google Scholar
• ANDERSON R, FELDMAN C, THERON AJ, RAIVIAFI G, COLE PJ, WILSON R: Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Br. J. Pharmacol. (1996) 117:1387–1394.
   PubMedGoogle Scholar
• SPOELSTRA FM, POSTMA DS, HOVENGA H, NOORDHOEK JA, KAUFFMAN HF: Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax (2002) 57:237–241.
   PubMed Web of Science ®Google Scholar
• EICKELBERG 0, ROTH M, LORX R et al.: Ligand-independent activation of the glucocorticoid receptor by 02-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol. Chem. (1999) 274:1005–1010.
   Google Scholar
• ••Experimental trial showing the effect ofsalmeterol on the translocation of corticosteroid receptors into the nuclear cell from the cytosol.
   Google Scholar
• PANG L, KNOX AJ: Synergistic inhibition by 02-agonists and corticosteroids on tumor necrosis factor-a-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am. J Respir. Cell Mol. Biol. (2000) 23:79–85.
   PubMed Web of Science ®Google Scholar
• KANKAANRANTA H, LINDSAY MA, GIEMBYCZ MA, ZHANG X, MOILANEN E, BARNES PJ: Delayed eosinophil apoptosis in asthma. J Allergy Clin. Immunol. (2000) 106:77–83.
   PubMed Web of Science ®Google Scholar
• NIELSON CP, HADJOKAS NE: 0-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am. J. Respir. Grit. Care Med. (1998) 157:184–191.
   PubMedGoogle Scholar
• TAN KS, GROVE A, MCLEAN A, GNOSSPELIUSY, HALL IP, LIP WORTH BJ: Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am. J Respir. Grit. Care Med. (1997) 156:28–35.
   PubMedGoogle Scholar
• HJEMDAHL P, ZETTERLUND A, LARSSON K:132-agonist treatment reduces 02-sensitivity in alveolar macrophages 38 despite corticosteroid treatment. Am. J Respir. Grit. Care Med. (1996) 153:576–581.
   PubMedGoogle Scholar
• YATES DH, KHARITONOV SA, BARNES PJ: An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled132-agonist. Am. J Respir. Grit. Care Med. (1996) 154:1603–1607.
   PubMed Web of Science ®Google Scholar
• REYNISDOTTIR S, WAHRENBERG H, BYLIN G, ARNER P: Effect of glucocorticosteroid treatment on 13-adrenoceptor subtype function in adipocytes from patients with asthma. Sci. (Land.) (1993) 85:237–244.
   PubMedGoogle Scholar
• ORSIDA BE, WARD C, LI X et al.: Effect of a long-acting 132-agonist over three months on airway wall vascular remodeling in asthma. Am. J Respir. Grit. Care Med. (2001) 164:117–121.
   PubMedGoogle Scholar
• ••Single trial comparing the effect ofsalmeterol and FP on the vascular component on airway remodelling.
   Google Scholar
• BONNER JC, BADGETT A, LINDROOS PM, COIN PG: Basic fibroblast growth factor induces expression of the PDGF receptor-a on human bronchial smooth muscle cells. Am. J Physiol. (1996) 271:L880–L888.
   Google Scholar
• Guidelines for the diagnosis and management of asthma. Update on selected topics-2002. National Institutes of Health. National Heart, Lung, and Blood Institute. National asthma education and prevention program (2002) Bethseda, MD, USA.
   Google Scholar
• VERBERNE AA, FROST C, ROORDA RJ, VAN DER LH, KERREBIJN KF: One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am. J. Respir. Grit. Care Med. (1997) 156:688–695.
   PubMed Web of Science ®Google Scholar
• SIMONS FE: A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N. Engl. J Med. (1997) 337:1659–1665.
   PubMed Web of Science ®Google Scholar
• PRIMHAK RA, SMITH CM, YONG SC et al.: The bronchoprotective effect of inhaled salmeterol in preschool children: a dose-ranging study. Eur. Respir. J. (1999) 13:78–81.
   PubMedGoogle Scholar
• BISGAARD H, GILLIES J, GROENEWALD M, MADEN C: The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am. J Respir. Grit. Care Med. (1999) 160:126–131.
   PubMed Web of Science ®Google Scholar
• ROORDA RJ, MEZEI G, BISGAARD H, MADEN C: Response of preschool children with asthma symptoms to fluticasone propionate]. Allergy Clin. Immunol. (2001) 108:540–546.
   Google Scholar
• VISSER MJ, POSTMA DS, ARENDS LR, DE VRIES TW, DUIVERMAN EJ, BRAND PL: One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height. Am. J. Respir. Grit. Care Med. (2001) 164:2073–2077.
   PubMedGoogle Scholar
• BISGAARD H, PRICE MJ, MADEN C, OLSEN NA: Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children. Chest (2001) 120:1835–1842.
   PubMedGoogle Scholar
• PAO CS, MCKENZIE SA: Randomized controlled trial of fluticasone in preschool children with intermittent wheeze. Am. J Respir. Grit. Care Med. (2002) 166:945–949.
   PubMed Web of Science ®Google Scholar
• GREEN RH, BRIGHTLING CE, WOLTMANN G, PARKER D, WARDLAW AJ, PAVORD ID: Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax (2002) 57:875–879.
   PubMed Web of Science ®Google Scholar
• DOUWES J, GIBSON P, PEKKANEN J, PEARCE N: Non-eosinophilic asthma: importance and possible mechanisms. Thorax (2002) 57:643–648.
   PubMed Web of Science ®Google Scholar
• LE BOURGEOIS M, GONCALVES M, LE CLAINCHE Let al.: Bronchoalveolar cells in children 3 years old with severe recurrent wheezing. Chest (2002) 122:791–797.
   Google Scholar